• Subjects Acute lymphocytic leukaemia Cancer therapeutic resistance Drug therapy TheOriginal Articlewas published on 18 May 2011 Correction to:Naturehttps://doi.org/10.1038/nature09883Published online 18 May 2011 In the version of this article initially published, the panel “Adriamycin/BCL6+/+” in Fig. • 2d represents another image of the “Control/BCL6−/−” condition. • The error occurred during figure assembly and did not affect the calculation of mean values and s.d. • Our own image analysis, not available at the time of publication, revealed that the panel “SFO2/Imatinib” in Supplementary Fig. • 21 contained an inadvertent duplication. • The corrected figure panels are provided below as Figs.1and2.
Article Summaries:
- Correction to 2011 Nature study on BCL6 and Ph⁺ ALL
Nature published a correction for the 2011 article “BCL6 enables Ph⁺ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition.” The authors identified two figure assembly errors: an image in Fig. 2d labeled “Adriamycin/BCL6+/+” was a duplicate of the “Control/BCL6−/−” panel, and a panel in Supplementary Fig. 21 (SFO2/Imatinib) was inadvertently duplicated. The errors did not affect the reported mean values or standard deviations. Corrected figure panels are now provided, and the original raw images and flow‑cytometry data have been deposited on Mendeley Data. The notice formally amends the record.
Sources: